Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Biochim Biophys Acta 1832, 542552, doi: 10.1016/j.bbadis.2012.12.011 (2013)
Serefoglu, E
One investigator
These CVOT findings are supported by a real-world study performed in over 3 million patients with T2DM from the United States, in which patients treated with SGLT2is did not have a higher risk of any or lower amputation compared with incretins or other glucose-lowering agents [77]
Coverage requires BMI 30 or 27 with comorbidities and documentation of prior lifestyle modification attempts
US$ 27.63
US$ 22.58
US$ 27.18
US$ 29.62
US$ 25.78
US$ 21.89
US$ 28.05
US$ 25.39
US$ 23.24
US$ 20.38
US$ 24.72
US$ 24.39
